Table 2.
Chronologic Age–Adjusted Logistic Regression Models Assessing Relationships Between Covariates and More Advanced Reproductive Age
| Proportional Oddsa | |||
|---|---|---|---|
| Covariateb | OR (95% CI) | Pairwise P Valuec | Overall P Value |
| Age (per 1 y)d | 1.49 (1.44–1.54) | … | <.01 |
| Race | |||
| Asian vs White | 0.77 (.48–1.23) | … | 0.1 |
| Black or African American vs White | 1.10 (.73–1.65) | … | |
| Other vs White | 1.42 (.76–2.65) | … | |
| Enrollment region | |||
| Latin America and Caribbean vs High Income | 1.59 (1.08–2.33) | .02 | <.01 |
| Southeast, East, and South Asia vs High Income | 0.95 (.64–1.41) | .79 | |
| Sub-Saharan Africa vs High Income | 1.50 (1.07–2.11) | .02 | |
| Smoking status | |||
| Current vs never | 1.21 (.81–1.79) | … | .15 |
| Former vs never | 0.74 (.51–1.09) | … | |
| Intravenous drug use (former vs never) | 0.55 (.23–1.27) | … | .16 |
| BMIe | |||
| <18.5 vs 18.5–24.9 | 1.47 (.68–3.20) | … | .10 |
| 25–29.9 vs 18.5–24.9 | 1.01 (.73–1.38) | … | |
| 30–34.9 vs 18.5–24.9 | 1.54 (1.04–2.28) | … | |
| ≥35 vs 18.5–24.9 | 0.86 (.58–1.27) | … | |
| Waist circumference (>88 vs ≤88 cm) | 1.38 (1.06–1.80) | … | .02 |
| Total cholesterol (mg/dL) | |||
| 160–199 vs <160 | 0.99 (.69–1.42) | … | .14 |
| 200–239 vs <160 | 1.15 (.79–1.67) | … | |
| ≥240 vs <160 | 1.73 (1.01–2.95) | … | |
| HDL-C (per 10 mg/dL) | 1.06 (.98–1.14) | … | .16 |
| eGFR (CKD-EPI) (per 10 mL/min/1.73 mm2) | 1.06 (.99–1.13) | … | .11 |
| Hemoglobin (≥12 vs <12 g/dL) | 2.32 (1.71–3.14) | … | <.01 |
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration equation; eGFR, estimated glomerular filtration rate; HDL-C, HDL-C, high-density lipoprotein cholesterol; OR, odds ratio.
aEstimates are from cumulative logistic regression models with proportional odds, ORs and CIs are shown. Under the proportional odds, the OR for women with undetectable versus detectable anti-müllerian hormone is the same as the OR for women with the last menstrual period >12 months earlier versus within the last 12 months. The proportional odds assumption was validated by the score test for all models. See the Statistical Methods section for more details.
bContinuous covariates were assessed for linearity and were presented categorically if the interpretation changed.
Only models with an overall P value < .2 are presented; the following covariates were considered and are not shown: substance use, history of hypertension, triglycerides, low-density lipoprotein cholesterol level, duration of human immunodeficiency virus infection (years), CD4 cell count, duration of ART exposure (years), ART regimen, depression medications, chronic active hepatitis B virus, and chronic active hepatitis C virus.
cFor covariates with >2 levels, pairwise P values for comparison to the reference were provided when the overall P value was <.05.
dEstimate from a univariate model.
eBMI is calculated as weight in kilograms divided by height in meters squared.